

"CMR International 2009 Pharmaceutical R&D Factbook"


Thomson Reuters, 2009, 96 pages, \$3,990

Review by Norman M. Goldfarb

"CMR International 2009 Pharmaceutical R&D Factbook" presents the most important results from CMR performance benchmarking programs in 74 figures in nine chapters:

- Overview
- R&D resources
- R&D pipeline volume
- Success rates
- Cycle times
- Regional comparisons
- Therapeutic area focus
- Biopharmaceutical focus
- Clinical functions
- Patents
- Global generics market

The following sample chart summarizes disconcerting R&D trends in the industry:



The implications of each chart are summarized. For a delightful change from most data in the industry, descriptions of methodology, definitions and data sources provide assurance that the charts mean what they claim to mean.

A few of the many fascinating findings include:

- The 23 new active substances (NAS) first launched onto the world market in 2008 is an all time low. ("New active substances" include 21 new molecular entities (NME) (including biologics) plus radiopharmaceuticals.)
- Clinical research consumes 37% of R&D expenditures.
- The number of active substances entering Phase I trials increased by 6% in 2008, but the number entering Phase II trials dropped by 12% and the number entering Phase III trials plunged by 42%.
- In 2008, 33% of NMEs were first marketed in the U.S., down from 61% in 2006 and 46% in 2004.
- Thirty-one percent of anti-infective NASs that reach the stage of first patient dose are successfully marketed, compared to 12% of CNS drugs.
- Fifty-one percent of new biopharmaceutical entities (NBE) that reach the stage of first patient dose are successfully marketed, compared to 19% of new chemical entities (NCE).

The book is available at <http://cmr.thomsonreuters.com/shop>. An enterprise version with access to the underlying data in MS PowerPoint is also available for \$9,990.

Reviewer

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Contact him at 1.650.465.0119 or ngoldfarb@firstclinical.com.